Pfizer Unit Recalls Pain Drug Embeda
The recall, announced Friday, comes just several weeks after Pfizer completed its $3.6 billion acquisition of King. The drug is being recalled because routine testing discovered that one of its main compounds was degenerating faster than it should, said Pfizer spokesman Rick Chambers.
The recall is unlikely to pose a safety...
To view the full article, register now.